Multiple Myeloma

The treatment of multiple myeloma has changed dramatically in recent years. Following research and therapeutic breakthroughs, it is time to debunk some of the most common myths about the disease.

A new drug, iberdomide (Zanvexus), has been approved by the FDA for the treatment of adults with relapsed or refractory multiple myeloma. Its combination with other drugs nearly doubled the rate of patients in whom no evidence of the disease was found. It is still unclear whether this will translate into extended life. Dr. Julia Vaksman, from the Hematology Department at the Davidoff Center in...